Compare Public Service Enterprise Group Incorporated Common Stock (PEG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Service Enterprise Group Incorporated Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Public Service Enterprise Group Incorporated Common Stock trades at $69.9 (market cap $35.17B), while State Street SPDR S&P Biotech ETF trades at $147.52 (market cap $10.27B). The key difference: Public Service Enterprise Group Incorporated Common Stock is far larger — about 3.4× State Street SPDR S&P Biotech ETF's market cap, and Public Service Enterprise Group Incorporated Common Stock pays a 3.8% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Public Service Enterprise Group Incorporated Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| PEG | XBI | |
|---|---|---|
Market Cap | $35.17B | $10.27B |
Volume | 2,725,742 | 9,751,587 |
Sector | Utilities | Broad Market / Factor |
52-Week High | $86.95 | $169.55 |
52-Week Low | $66.56 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $59.65B | — |
Dividend Yield | 3.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Service Enterprise Group (PEG) trades at $70.47, down 0.41% on the day, showing neutral technical signals with support at $70 and resistance at $71. The company maintains solid fundamentals with a 17.53 P/E ratio and consistent earnings beats in recent quarters, though Q3 2026 results are pending. Revenue grew to $12.17B in 2025 with a healthy 16.04% net income margin, while analyst consensus remains mixed with a $83.40 price target suggesting potential upside.
PEG presents a stable utility investment with regulated growth and nuclear assets supporting a 6-8% earnings outlook. Key risks include regulatory approvals for capex plans and interest rate sensitivity. Institutional buying and a 15-year dividend growth streak add appeal, but recent CEO stock sales and proximity to 52-week lows warrant caution amid sector volatility.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Public Service Enterprise Group Incorporated Common Stock
Public Service Enterprise Group Incorporated is a New Jersey-based utility holding company operating through Public Service Electric and Gas Co. (PSE&G), which transmits and distributes electricity and distributes natural gas, and PSEG Power, which operates the Salem and Hope Creek nuclear generating stations. It also runs the Long Island Power Authority's electric system under contract via PSEG Long Island.
Read more on PEG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
